ACADIA Pharmaceuticals(US:ACAD)2026-02-25 22:32Financial Data and Key Metrics Changes - Acadia reported adjusted total revenues of $298 million in Q4 2025, a 16% increase from the prior year, and annual revenues exceeded $1 billion for the first time, reaching $1.08 billion, representing a 14% growth from the previous year [6][24] - Adjusted NUPLAZID net sales were $189 million in Q4, up 17% year-over-year, and $692 million for the full year, up 15% [7][27] - DAYBUE achieved net product sales of $110 million in Q4, representing a 13% year-over-year increase, and $391 million for the full year, up 12% [8][28] Business Line Data and Key Metrics Changes - NUPLAZID's volume growth was 13% in Q4 and 9% for the full year, with new prescriptions growing 18% year-over-year in Q4 [13][15] - DAYBUE's sales growth was driven by expanded reach into community physician settings and international patient supply programs [8][19] - DAYBUE STIX, a new powder formulation, is generating significant interest and is expected to unlock additional patient opportunities [17][19] Market Data and Key Metrics Changes - The U.S. market for NUPLAZID and DAYBUE continues to show strong demand, with 76% of new DAYBUE prescriptions originating from community-based physicians [16][19] - DAYBUE Liquid is now approved in three international markets, including Israel, expanding Acadia's global footprint [18] Company Strategy and Development Direction - Acadia aims for NUPLAZID to achieve blockbuster status with $1 billion in net sales by 2028, with 2026 guidance for NUPLAZID net sales between $760 million and $790 million [7][30] - The company is focused on expanding its R&D pipeline, with several key studies and potential new product launches planned [20][23] - Acadia is committed to advancing access to trofinetide in the EU despite recent regulatory challenges [9][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, supported by strong commercial execution and a robust pipeline [6][33] - The anticipated phase II readout of remlifanserin in Alzheimer's disease psychosis is expected to be a significant milestone for the company [11][33] - The company is well-positioned for sustained growth and value creation, with a strong balance sheet allowing for business development opportunities [33] Other Important Information - The company reported a one-time non-cash income tax benefit of approximately $250 million due to the release of a valuation allowance on deferred tax assets [29] - R&D expenses for 2026 are expected to be between $385 million and $410 million, reflecting increased clinical and personnel costs [31][32] Q&A Session Summary Question: How should we think about ramp to your 2028 global net sales targets? - Management expects low to mid-teens growth for NUPLAZID and low 20% growth for DAYBUE, projecting a CAGR of about 16% through 2028 [36][37] Question: What does good remlifanserin ADP data look like later this year? - The focus is on showing efficacy and a good safety profile, with a moderate effect size powered for the primary endpoint [43][47] Question: Can you provide insights on DAYBUE's persistency and patient compliance? - Discontinuation rates remain in the low single-digit range, and the business is stabilizing with a focus on growth through community expansion [51][53] Question: What is the timeline for the upcoming phase III trial in ADP? - The transition from phase II to phase III enrollment is expected later this year, with operationally seamless execution [61] Question: How does remlifanserin differentiate from COBENFY? - Mechanistically, remlifanserin and COBENFY approach psychosis differently, with remlifanserin expected to have a favorable safety profile [67][68]